Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06465641 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Methylphenidate in KBG Syndrome: N-of-1 Series

Study acronym: KBGS_N_of_1
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Jan 1, 2027 → Jan 1, 2028
See other at-risk trials from Radboud University Medical Center

Record History

  1. Primary completion pushed from Jan 1, 2027 to Jan 1, 2028
    • Study completion pushed from Oct 1, 2027 to Oct 1, 2028
    v3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Sep 1, 2024 to Nov 13, 2024
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial\] is to learn about the effect of methylphenidate in children and adolescents with KBG syndrome. The main question it aims to answer is: • What is the effectiveness of methylphenidate on attention deficit and ADHD-related symptoms in children and adolescents with KBG syndrome? Participants will receive multiple blocks of treatment with methylphenidate and placebo and fill out various questionnaires.
Trial Details
NCT Number NCT06465641
Lead Sponsor Radboud University Medical Center
Conditions
(from sponsor)		 Kbg Syndrome, ADHD - Combined Type
Related terms KBG syndrome
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov